Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.38 |
| ▸ | HTT | P42858 | 2/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | GLA | P06280 | 1/20 | 0.36 |
| ▸ | PTGDR2 | Q9Y5Y4 | 3/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.34 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3777981 | 0.94 | TSHR (0.37) | TSHRHTTGAASMN1; SMN2ALDH1A1 | |
| SCHEMBL3780006 | 0.92 | PTGDR2 (0.44) | PTGDR2 | |
| SCHEMBL3776310 | 0.90 | TSHR (0.38) | TSHRHTTGAASMN1; SMN2ALDH1A1 | |
| SCHEMBL3776854 | 0.88 | TSHR (0.42) | TSHRHTTGAASMN1; SMN2ALDH1A1 | |
| SCHEMBL3782104 | 0.87 | TSHR (0.38) | TSHRHTTGAASMN1; SMN2ALDH1A1 | |
| SCHEMBL3770462 | 0.86 | PTGDR2 (0.44) | PTGDR2 | |
| SCHEMBL3777797 | 0.84 | MAPT (0.38) | TSHRHTTGAASMN1; SMN2ALDH1A1 | |
| SCHEMBL3772456 | 0.83 | ALDH1A1 (0.40) | TSHRHTTSMN1; SMN2ALDH1A1L3MBTL1 | |
| SCHEMBL3781075 | 0.81 | PTGDR2 (0.36) | TSHRHTTGAASMN1; SMN2ALDH1A1 | |
| SCHEMBL3786033 | 0.81 | PTGDR2 (0.40) | PTGDR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1928457-B1 | QUINOLINES AND THEIR THERAPEUTIC USE | PULMAGEN THERAPEUTICS ASTHMA LTD (GB) | 2012-12-12 | — | — | EP | disclosed |
| US-7858640-B2 | Quinolines and their therapeutic use | PULMAGEN THERAPEUTICS (ASTHMA) LIMITED (GB) | 2010-12-28 | — | — | US | disclosed |
| US-20090156600-A1 | Quinolines and Their Therapeutic Use | GB005, INC. | 2009-06-18 | — | — | US | disclosed |
| EP-1928457-A2 | QUINOLINES AND THEIR THERAPEUTIC USE | Argenta Discovery Limited (GB) | 2008-06-11 | — | — | EP | disclosed |
| WO-2007036743-A2 | QUINOLINES AND THEIR THERAPEUTIC USE | ARGENTA DISCOVERY LIMITED (GB) | 2007-04-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156600-A1 | Quinolines and Their Therapeutic Use | NR3C1, NR3C2, NR1H3 | TSHR 73/4885HTT 3597/4885GAA 4744/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.